Pricey new blood thinner might be safer for leg clots

July 1, 2013 by Brenda Goodman, Healthday Reporter
Pricey new blood thinner might be safer for leg clots
In trial, Eliquis worked as well as warfarin but with less risk of bleeding.

(HealthDay)—The new pill Eliquis prevents dangerous blood clots in the legs and lungs as well as standard therapy, though with less risk of serious bleeding, a new study shows.

The research, published online July 1 in the New England Journal of Medicine, may point doctors toward a simpler, if more costly, way to prevent repeat blood clots in patients at risk for venous thromboembolism.

Venous thromboembolism includes two related conditions: (DVT) and pulmonary embolism. Together, these conditions hospitalize more than 500,000 adults each year in the United States, according to the government's National Hospital Discharge Survey.

In DVT, a blood clot forms in the deep veins of the leg, causing swelling, redness, warmth and pain. If the blood clot breaks free, it can travel and lodge near the brain, heart or another vital organ, causing severe damage. If a clot blocks a blood vessel in the lungs, it's a life-threatening emergency called (PE). PEs are the third leading cause of after heart attacks and strokes.

Blood clots in veins can happen without warning, but certain factors increase a person's risk including obesity, , long-distance travel, , cigarette smoking, pregnancy or recent surgery or injury.

Once a person has had one venous clot, they're more likely to get another, so doctors will often prescribe medication to lower the risk.

For years, the medication doctors relied on to prevent blood clots was a drug called , which is also sold under the brand name Coumadin.

Warfarin works well, but it's also tricky to take. Patients on the drug need regular blood tests—these can be weekly at the start of treatment—to make sure they're taking the right dose. And the dose can change from day to day or week to week. There are also a number of foods and drugs that can interact with warfarin, interfering with its effectiveness.

"It's really challenging for elderly patients to get it all right," said senior study author Dr. Jeffrey Weitz, a professor of medicine at McMaster University in Ontario, Canada.

In December, the U.S. Food and Drug Administration approved the drug Eliquis. Like warfarin, Eliquis prevents , but it works in a slightly different way than the older medication. It also doesn't require regular blood tests or changing dosages, making it much easier to manage.

One drawback of Eliquis is its price. Mail-order pharmacies charge between $250 and $275 for a 30-day supply of the medication in the United States, according to the website pharmacychecker.com. Warfarin, on the other hand, is $4 for a 30-day supply at stores like Target and Walmart. That means that one Eliquis pill costs about as much as an entire month's supply of warfarin.

For the new study, researchers compared Eliquis to warfarin in nearly 5,400 patients with a history of venous thromboembolism. The average age of study participants was 57. Roughly 60 percent were men. Sixty-five percent had a history of DVT. About 25 percent had a history of PE. About 9 percent had both DVT and PE.

Half of the study participants took 10 milligrams (mg) of Eliquis twice daily for seven days, before dropping their dosage to 5 mg twice daily for six months. The other half started with twice daily injections of the blood-thinning drug Lovenox (low-weight heparin), followed by daily, personalized warfarin therapy.

After six months, 59 patients in the Eliquis group and 71 patients who got standard therapy had a new blood clot. Of those, 12 patients in the Eliquis group and 15 patients in the warfarin group died from clots, showing that both drugs worked about equally well.

But patients who took Eliquis had less serious bleeding than those who took warfarin. Out of 2,676 patients taking Eliquis, 15 had major bleeding on the drugs. Of 2,689 patients taking warfarin, 49 experienced major bleeding.

"That's almost a 70 percent reduction in major bleeding with Eliquis, compared to conventional therapy. That's huge," said Weitz.

Beyond serious bleeding, Weitz said people taking Eliquis also had less nuisance bleeding of the gums or nose, which can lead to stop taking their medication.

"I think it's very important," said Weitz, who reported that he has been a consultant for study sponsors Bristol-Myers Squibb and Pfizer, along with other pharmaceutical companies, within the past three years.

Another expert who wasn't involved in the study agreed.

"This new approach may simplify the treatment regimen, improve patient convenience and substantially increase the safety of venous thromboembolism treatment, making this an attractive new option," said Dr. Gregg Fonarow, who is co-director of the University of California, Los Angeles, preventive cardiology program at the David Geffen School of Medicine.

Explore further: New blood thinner beats older drug for vein clots

More information: For more on venous thromboembolism, head to the U.S. National Heart, Lung, and Blood Institute.

Related Stories

New blood thinner beats older drug for vein clots

February 20, 2013
(HealthDay)—People who need to take a blood thinner because they've had a clot in the deep veins of their legs appear to do better with the new drug Pradaxa (dibigatran) than with the older drug warfarin, researchers report.

New blood thinner may help prevent leg clots, study finds

December 10, 2012
(HealthDay)—The new anti-clotting drug apixaban (Eliquis) appears to help prevent potentially fatal blood clots in patients with deep vein thrombosis (DVT), a new Italian study finds.

Bristol-Pfizer anticlot drug gets key EU approval

November 20, 2012
European regulators have approved a crucial new anticlotting drug, Eliquis, for preventing strokes and dangerous clots in the circulatory system.

Anti-clot drug recommended for new approval in EU

September 21, 2012
(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...

Bristol-Myers, Pfizer's Eliquis approved in Japan

December 26, 2012
Regulators in Japan have approved sales of an anticlotting drug called Eliquis, developed by Bristol-Myers Squibb Co. and Pfizer Inc., that's a potential blockbuster in a new category of medicines to prevent strokes and heart ...

Aspirin may prevent recurrence of deep vein blood clots

May 23, 2012
(HealthDay) -- After suffering a type of blood clot called a venous thromboembolism, patients usually take a blood-thinner such as warfarin (Coumadin). But aspirin may do just as well after a period of time, according to ...

Recommended for you

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

January 2, 2018
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.